Claret Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.5M | Buy |
189,930
+3,414
| +2% | +$199K | 1.38% | 26 |
|
|
2025
Q4 | $10.1M | Sell |
186,516
-2,609
| -1% | -$126K | 1.17% | 26 |
|
|
2025
Q3 | $8.53M | Buy |
189,125
+2,766
| +1% | +$129K | 1.02% | 26 |
|
|
2025
Q2 | $8.63M | Buy |
186,359
+13,374
| +8% | +$657K | 1.12% | 23 |
|
|
2025
Q1 | $10.6M | Sell |
172,985
-1,638
| -0.9% | -$95.5K | 1.52% | 16 |
|
|
2024
Q4 | $9.88M | Buy |
174,623
+2,199
| +1% | +$123K | 1.56% | 15 |
|
|
2024
Q3 | $8.92M | Sell |
172,424
-655
| -0.4% | -$30.7K | 1.46% | 17 |
|
|
2024
Q2 | $7.19M | Buy |
173,079
+5,832
| +3% | +$261K | 1.28% | 19 |
|
|
2024
Q1 | $9.07M | Buy |
167,247
+21,183
| +15% | +$1.08M | 1.52% | 16 |
|
|
2023
Q4 | $7.5M | Buy |
146,064
+11,839
| +9% | +$621K | 1.34% | 18 |
|
|
2023
Q3 | $7.79M | Buy |
134,225
+1,323
| +1% | +$81.1K | 1.53% | 17 |
|
|
2023
Q2 | $8.5M | Buy |
132,902
+9,417
| +8% | +$631K | 1.66% | 18 |
|
|
2023
Q1 | $8.56M | Buy |
123,485
+28,258
| +30% | +$1.99M | 1.69% | 19 |
|
|
2022
Q4 | $6.85M | Sell |
95,227
-387
| -0.4% | -$29.2K | 1.51% | 20 |
|
|
2022
Q3 | $6.8M | Buy |
95,614
+207
| +0.2% | +$15K | 1.61% | 20 |
|
|
2022
Q2 | $7.35M | Buy |
95,407
+1,728
| +2% | +$132K | 1.58% | 20 |
|
|
2022
Q1 | $6.84M | Buy |
93,679
+20,175
| +27% | +$1.35M | 1.32% | 22 |
|
|
2021
Q4 | $4.58M | Buy |
73,504
+32,825
| +81% | +$1.93M | 0.85% | 30 |
|
|
2021
Q3 | $2.41M | Buy |
40,679
+8,178
| +25% | +$539K | 0.41% | 45 |
|
|
2021
Q2 | $2.17M | Buy |
32,501
+11,880
| +58% | +$775K | 0.36% | 46 |
|
|
2021
Q1 | $1.3M | Hold |
20,621
| – | – | 0.24% | 57 |
|
|
2020
Q4 | $1.28M | Sell |
20,621
-144
| -0.7% | -$8.86K | 0.25% | 59 |
|
|
2020
Q3 | $1.25M | Sell |
20,765
-64
| -0.3% | -$3.85K | 0.28% | 62 |
|
|
2020
Q2 | $1.23M | Buy |
20,829
+445
| +2% | +$26.6K | 0.29% | 64 |
|
|
2020
Q1 | $1.14M | Buy |
20,384
+9
| +0% | +$550 | 0.32% | 60 |
|
|
2019
Q4 | $1.31M | Buy |
20,375
+1,214
| +6% | +$69.5K | 0.25% | 68 |
|
|
2019
Q3 | $972K | Buy |
19,161
+2,128
| +12% | +$100K | 0.2% | 80 |
|
|
2019
Q2 | $772K | Buy |
17,033
+417
| +3% | +$19.4K | 0.16% | 87 |
|
|
2019
Q1 | $793K | Hold |
16,616
| – | – | 0.16% | 90 |
|
|
2018
Q4 | $864K | Sell |
16,616
-32
| -0.2% | -$1.72K | 0.19% | 85 |
|
|
2018
Q3 | $1.03M | Buy |
16,648
+651
| +4% | +$38.6K | 0.2% | 80 |
|
|
2018
Q2 | $885K | Sell |
15,997
-85
| -0.5% | -$4.59K | 0.18% | 86 |
|
|
2018
Q1 | $1.02M | Hold |
16,082
| – | – | 0.23% | 76 |
|
|
2017
Q4 | $986K | Buy |
+16,082
| New | +$1.01M | 0.22% | 84 |
|
Other funds holding BMY
VCM
VPM
Claret Asset Management's BMY Position: Q1 2026 in Review
Claret Asset Management increased its Bristol-Myers Squibb (BMY) stake by 1.8% in Q1 2026, buying an estimated $199K and bringing the position to 189,930 shares worth $11.5M. The position accounts for 1.38% of the portfolio, ranked #26.
Claret Asset Management first reported a position in BMY in Q4 2017 and has held it in 34 quarters since. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Claret Asset Management held 189,930 shares of Bristol-Myers Squibb worth $11.5M as of Q1 2026.
- Claret Asset Management bought 3,414 Bristol-Myers Squibb shares in Q1 2026, an estimated $199K.
- Bristol-Myers Squibb made up 1.38% of Claret Asset Management's portfolio in Q1 2026, its #26 holding.
- Claret Asset Management first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 34 quarters since.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Claret Asset Management's 13F filing for Q1 2026, filed 11 May 2026.